Artlegia (olokizumab) / R-Pharm 
Welcome,         Profile    Billing    Logout  
 14 Diseases   3 Trials   3 Trials   139 News 


123»
  • ||||||||||  Artlegia (olokizumab) - R / Pharm
    EFFECT OF OLOKIZUMAB ON THE NEUTROPHIL-LYMPOCYTE RATIO IN PATIENTS WITH RHEUMATOID ARTHRITIS (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_1234;    
    P3
    Post hoc analysis of CREDO 1-3 showed an association of direct IL-6 blockade by olokizumab and NLR decrease, which was connected with the neutrophil component reduction. NLR changes correlated with changes in RA activity indices and laboratory parameters.
  • ||||||||||  Journal:  Text Mining and Drug Discovery Analysis: A Comprehensive Approach to Investigate Diabetes-Induced Osteoporosis. (Pubmed Central) -  Jan 26, 2024   
    After DGI analysis, we identified 7 genes targeted by 11 drugs, which represent candidates for treating DOP. This study unveils ANDECALIXIMAB, SILTUXIMAB, OLOKIZUMAB, SECUKINUMAB, and IXEKIZUMAB as promising potential drugs for DOP treatment, demonstrating the significance of utilizing text mining and pathway analysis to investigate disease mechanisms and explore existing therapeutic options.
  • ||||||||||  Review, Journal:  Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned? (Pubmed Central) -  Nov 22, 2023   
    In addition, the efficacy and safety of tocilizumab and sarilumab have led to a rapid investigation of biosimilars and new potent IL-6 receptor blockers. A comprehensive understanding of mechanisms of this pathway with further long-term clinical data and basic research may provide a decisive impact on selecting the appropriate mechanism as the first choice in personalized treatments.
  • ||||||||||  Artlegia (olokizumab) - R / Pharm
    Efficacy of Olokizumab in Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of a Study (Poster Hall; in person) -  Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4128;    
    OKZ has an antidepressant effect, leads to a decrease in the frequency of sleep disorders, but a complete regression of depression was also found in 22% of patients who received OKZ without PPT, mainly in patients with mild depression. The combination of OKZ and PPT was optimal for the complete regression of depression, anxiety and a decrease in the frequency and severity of CI.
  • ||||||||||  Artlegia (olokizumab) - R / Pharm, Actemra IV (tocilizumab) / Roche, JW Pharma, Ilsira (levilimab) / Biocad
    Journal:  Clinical cases of complicated diverticulitis against the background of severe course COVID-19. Case report (Pubmed Central) -  May 15, 2023   
    The second patient received levilimab on the 3rd day of his stay in the hospital...Both patients died. Thus, when using targeted therapy for patients with COVID-19, it is necessary to take into account that they may have previously undiagnosed chronic diseases that can cause fatal complications against the background of immunosuppression.
  • ||||||||||  Journal:  Identification of potential molecular mechanisms and candidate drugs for radiotherapy- and chemotherapy-induced mucositis. (Pubmed Central) -  Mar 21, 2023   
    Through our data mining, bioinformatics survey, and candidate drug selection, TNF, IL-6, and TLR9 could play an important role in disease progression and treatment. In addition, eight candidate drugs (olokizumab, chloroquine, hydroxychloroquine, adalimumab, etanercept, golimumab, infliximab, and thalidomide) were selected by the drug-gene interaction literature search additionally, as candidates for treating RIOM and CIOM.
  • ||||||||||  Artlegia (olokizumab) - R / Pharm
    Enrollment closed, Trial completion date, Trial primary completion date:  RESET: Study of Efficacy of Different Treatment Regimens of Olokizumab (clinicaltrials.gov) -  Feb 13, 2023   
    P3,  N=198, Active, not recruiting, 
    In addition, eight candidate drugs (olokizumab, chloroquine, hydroxychloroquine, adalimumab, etanercept, golimumab, infliximab, and thalidomide) were selected by the drug-gene interaction literature search additionally, as candidates for treating RIOM and CIOM. Recruiting --> Active, not recruiting | Trial completion date: May 2022 --> Apr 2023 | Trial primary completion date: Apr 2022 --> Oct 2022
  • ||||||||||  Artlegia (olokizumab) - R / Pharm, Humira (adalimumab) / Eisai, AbbVie
    The Impact of Comorbidities on the Efficacy of IL-6 Inhibitor Olokizumab Compared to Adalimumab (Virtual Poster Hall) -  Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_1588;    
    P3
    In the group of RA patients treated with ADA, presence of at least one additional comorbid condition (high CCI) was associated with significantly lower treatment efficacy.Abbreviations: ACR 20, 20% improvement in the American College of Rheumatology criteria; ACR 50, 50% improvement in the American College of Rheumatology criteria; CDAI, Clinical Disease Activity Index; CI, Confidence interval; DAS28 (CRP), Disease Activity Score 28-joint count based on C-reactive protein; SDAI, Simplified Disease Activity Index. Bold font of p-values indicates statistical significance.Abbreviations: ACR 20, 20% improvement in the American College of Rheumatology criteria; ACR 50, 50% improvement in the American College of Rheumatology criteria; CDAI, Clinical Disease Activity Index; CI, Confidence interval; DAS28 (CRP), Disease Activity Score 28-joint count based on C-reactive protein; SDAI, Simplified Disease Activity Index.
  • ||||||||||  Artlegia (olokizumab) - R / Pharm
    Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis – Results of an Open-Label Extension Study (Virtual Poster Hall) -  Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_1582;    
    P3
    Efficacy of OKZ was maintained through Wk 82 in pts who continued in the OLE study with low discontinuation rates.RTable. Overall Summary of Adverse Events and Immunogenicity (Safety Population).Abbreviations: ADA, antidrug antibodies; AE, adverse event that occurred after the first dose of the open-label (OLE) study treatment; ALT, alanine aminotransferase; BL, baseline; n, number of subjects; Nab, neutralizing antibodies; q2w, every 2 weeks; q4w, every 4 weeks; ULN, upper limit normal; %, percentage of subjects calculated relative to the total number (N) of subjects in the population.Footnotes: 1 - Psoriasis, cutaneous vasculitis, alopecia areata, hypersensitivity vasculitis, pyoderma gangrenosum, vasculitic rash, vitiligo; 2 - Chronic gastritis, ulcerative keratitis, ocular myasthenia, vasculitis, rheumatoid vasculitis, autoimmune thyroiditis, type 1 diabetes mellitus, rheumatoid lung.3 - AEs leading to death by System Organ Class: infections and infestations 7 (0.3%), general disorders and administration site conditions 5 (0.2%), cardiac disorders 3 (0.1%), neoplasms benign, malignant and unspecified (CNS neoplasm, metastatic neoplasm, pancreatic carcinoma metastatic) 3 (0.1%).Figure 1.
  • ||||||||||  Artlegia (olokizumab) - R / Pharm, Humira (adalimumab) / Eisai, AbbVie
    Journal:  Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. (Pubmed Central) -  Aug 31, 2022   
    P3
    Larger and longer trials are required to determine the efficacy and safety of olokizumab in patients with rheumatoid arthritis. (Supported by R-Pharm; CREDO2 ClinicalTrials.gov number, NCT02760407.).
  • ||||||||||  Journal:  Drug discovery in spinal cord injury-induced osteoporosis: a text mining-based study. (Pubmed Central) -  Aug 14, 2022   
    Taken together, siltuximab, olokizumab, clazakizumab and BAN2401 were first discovered to become the potential drugs for the treatment of SCI-induced OP. Drug discovery using text mining and pathway analysis is a significant way to investigate the pathomechanism of the disease while exploring existing drugs to treat the disease.
  • ||||||||||  Artlegia (olokizumab) - R / Pharm
    Enrollment open, Enrollment change, Trial completion date, Trial primary completion date:  ROCOVI: Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection (clinicaltrials.gov) -  Jul 1, 2022   
    P=N/A,  N=3000, Recruiting, 
    Drug discovery using text mining and pathway analysis is a significant way to investigate the pathomechanism of the disease while exploring existing drugs to treat the disease. Completed --> Recruiting | N=1911 --> 3000 | Trial completion date: Dec 2021 --> Aug 2022 | Trial primary completion date: Dec 2021 --> Aug 2022
  • ||||||||||  Artlegia (olokizumab) - R / Pharm
    Journal, IO biomarker:  Genetic and Clinical Factors Associated with Olokizumab Treatment in Russian Patients with Rheumatoid Arthritis. (Pubmed Central) -  Apr 24, 2022   
    A high predictive value of the response to olokizumab therapy at 24 weeks was found for the combination of HLA-DRB1*04 and HLA-B*27 alleles with SNPs located in non-HLA genes (IL1B, IL17A, PADI4, DHODH, GLCCI1, IL23R, and TNFAIP3), and clinical characteristics (age, RA duration, and intensity) according to ACR20. Thus, the comprehensive assessment of polymorphic variants of HLA and non-HLA genes considering population characteristics in combination with clinical parameters allows for the elaboration of an RA prognostic panel.
  • ||||||||||  Efficacy of Biologics and Targeted Synthetic Drugs Approved in Russia to Treat Adults with Active Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis (Virtual) -  Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1423;    
    We conducted a systematic search for RCTs evaluating the efficacy of biologics (adalimumab, golimumab, levilimab, olokizumab, sarilumab, tocilizumab, infliximab, rituximab, certolizumab pegol, abatacept and etanercept) and tsDMARDs (tofacitinib, baricitinib and upadacitinib), both in combination with conventional synthetic DMARDs (csDMARDs) and in monotherapy for the treatment of adults with active RA...The proportion of patients with an inadequate response to previous methotrexate therapy was at least 50% in the included RCTs...Conclusion. Given the predominantly comparable relative effectiveness of the analyzed drugs, health professionals should also consider other factors, when choosing a treatment option for adults with active RA.
  • ||||||||||  Artlegia (olokizumab) - R / Pharm, Sylvant (siltuximab) / Jazz
    Biomarker, Journal:  A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential. (Pubmed Central) -  Mar 5, 2022   
    HZ-0408b is comparable to Olokizumab, a humanized mAb against IL-6 that is already in phase III studies...Most importantly, we proved that HZ-0408b treatment significantly ameliorated joint swelling after the onset of arthritis and dramatically reduced plasma C-reactive protein (CRP) levels in a monkey collagen-induced arthritis (CIA) model. Collectively, our findings using non-human primates indicate that humanized anti-IL-6 mAb HZ-0408b has excellent safety and efficacy profiles for RA therapy.
  • ||||||||||  olokizumab (CDP-6038) - R / Pharm
    [VIRTUAL] Experience of olokizumab use in COVID-19 patients () -  Jul 29, 2021 - Abstract #ERS2021ERS_2139;    
    Primarily, it affects the severity of clinical parameters by improving the general condition already on the first day of observation, and decreasing body temperature to normal values. The changes in the CRP levels show a significant effect of the IL-6 inhibitor on the systemic inflammatory response.